The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Intercept gets FDA breakthrough therapy status for Obeticholic acid to treat NASH with liver fibrosis.....           Janssen's PREZCOBIX gets FDA approval to treat adults living with HIV-1.....           USPTO issues patent for VG Life Sciences covering treatment of IBD with CLIP-Inducing agent.....           Reata enrolls first patient in Phase II/III MOXIe study of RTA 408 in friedreich's ataxia patients.....           AstraZeneca to use CRISPR genome editing technology for key therapeutic areas.....           India warns drugmakers failure not an option for price data due next week.....           Lilly's sales and earnings continue their free-fall but CEO Lechleiter sees good things coming.....           Viehbacher's ouster, severance raise red flags for CEO candidates.....           Victoza powers Novo's strong year; CEO projects growth for 2015.....           Study of all data on Roche's highly debated Tamiflu says it does help.....           AbbVie rides high on Humira sales in Q4 but looks to new products for success in 2015.....           Valeant forays into oncology with stalking-horse bid for Dendreon's Provenge.....           Bristol-Myers' Evotaz gets FDA approval for HIV-1 treatment in adults.....           OncoMed's cancer drug tarextumab gets FDA orphan drug status.....           FDA approves Pharmacyclics and Janssen' Imbruvica to treat Waldenstrom's macroglobulinemia.....           International Stem Cell to begin Phase I/IIa Parkinson's disease trial in Australia.....           Endo completes $2.6bn acquisition of Auxilium.....           Astellas to develop Immunomic's JRC2-LAMP-vax to treat Japanese red cedar pollinosis.....           MediciNova gets new patent covering MN-029 (denibulin) di-hydrochloride in Japan.....           Sorrento completes patient enrollment in Cynviloq TRIBECA registrational trial.....           Applied Molecular Transport, Janssen enter research and license deal for IBS therapy.....           Lupin now free to make a $1B deal with foreign investors, thanks to Indian cabinet decision.....           Pakistan's proposed drug-pricing policy, two years in the making, satisfies no one.....           Trans-Pacific trade talks on biologics not even close to agreement: USTR.....           Gilead zooms past AbbVie in hep C race with UnitedHealth deal.....           Ex-FDA chief testifies against J&J in Risperdal liability case.....           Looking to get out of the hot seat, Salix to restate financials for past 7 quarters.....           New Celgene meds power forward, but Revlimid's still the Big Kahuna.....           Branded drug prices leapt almost 15% last year, led by pain pills, COPD and heart meds.....           Novartis reports positive results from Jakavi Phase III trial in patients with polycythemia vera.....           FDA accepts MediciNova's IND for MN-001 to treat NASH.....           Galmed and Perrigo in manufacturing services agreement for aramchol API production.....           European Commission approves GSK and Novartis' three-part transaction.....           FDA grants orphan drug status for RestorGenex' RES-529 to treat glioblastoma multiforme.....           RegeneRx, G-treeBNT form joint venture to develop RGN-259 in US.....           Goodwin, Transporin enter technology collaboration to improve ability of antibody drug conjugates.....           Adamis receives notice of allowance for US and Japanese patents for dry powder inhaler Taper DPI.....           AgeneBio secures ADDF grant for new approach to delaying onset of Alzheimer's Dementia.....           Sumitomo Chemical develops SumiLarv 2 MR to prevent dengue fever.....           MacroGenics, Janssen end license deal for MGD011 to treat multiple b-cell malignancies.....           Emerging Asian pharma markets poised to show solid growth in 2015: report.....           UAE forces pharma to cut prices on 280 meds as weak oil prices hit.....           Armed with Indian approval, Gilead forges ahead with Sovaldi and its licensed copies.....           Roche misses the mark in 2014 despite sales wins.....           Mylan said to be eyeing a $7B-plus bid for rising star Hikma.....           Novartis braces for psoriasis pricing war as it preps for Cosentyx launch.....           Amgen zooms past $20B in sales, sparked by Enbrel, Neupogen and denosumab.....           Bayer, PHRI and C-SPIN to conduct Phase III trial of rivaroxaban to treat ESUS patients.....           Moberg Pharma gets Chinese approval for Kerasal Nail.....           Some OTC drugs linked to increased chance of dementia: study.....           Amgen seeks approval for myeloma drug Kyprolis in US and Europe.....           Vifor Pharma hyperphosphatemia drug Velphoro gets Swissmedic approval.....           Apricus Biosciences announces issuance of US Patent for RayVa.....           WCCT Global to collaborate with Dr Garry Nolan's Laboratory to explore systems-level host responses to influenza.....           Annette Funicello funds promising neurovascular research.....           Council for Responsible Nutrition releases guidelines on Iodine in Multivitamin/Mineral supplements for pregnancy and lactation.....           Takeda launches Fomepizole Intravenous Infusion 1.5g in Japan.....           Envisia begins Phase IIa trial of ENV515 to treat glaucoma patients.....           Bosch expands CPS portfolio for serialization of pharmaceutical packaging.....           Eisai, Ajinomoto launch Livamin oral granules in Philippines.....           Gilead expands hepatitis C generic licensing agreements to include investigational NS5A inhibitor GS-5816.....           Plandai secures collaboration agreement to further cannabis research in Uruguay.....           Actavis to buy Auden Mckenzie for GBP306m.....           U.S., India make incremental IP headway during Obama visit.....           Novartis Q4 profit slumps nearly 27% as sales take a hit.....           Pharmaceuticals and biotech a backdrop to China-Taiwan economic talks.....           Bristol-Myers braces for Abilify patent loss, predicting big sales drop for 2015.....           With generic losses on the horizon, Pfizer puts up a stormy 2015 forecast.....           J&J employee sniffs out spy camera in unisex bathroom.....           Novartis eyes more cost-cutting moves to deliver faster-growing profits.....           Pfizer extricates itself from investor suit with $400M settlement.....           FDA accepts for priority review Sanofi and Regeneron's BLA for hypercholesterolemia drug Praluent.....           EMA committee issues positive opinion for Merck's Sivextro to treat ABSSSI.....           Opsona starts OPN-305 Phase I/II trial to treat myelodysplastic syndrome.....           CEL-SCI secures approval in Romania to start Phase III Multikine trial.....           Enlivex secures EU orphan drug status for ApoCell to treat GvHD.....           Synageva starts dosing in Phase I/II trial of SBC-103 to treat MPS IIIB.....           Novartis' Jakavi recommended by CHMP for EU approval to treat polycythemia vera.....           Novartis' Bexsero vaccine gets FDA approval for prevention of meningitis B.....           FDA approves Natpara for injection to control hypocalcemia in patients with hypoparathyroidism.....           BioCryst gets FDA fast track status for BCX4161 to treat Hereditary Angioedema.....           Bayer's aflibercept solution for injection gets recommendation for approval in EU.....           India's Sun Pharma looks ahead on verge of Ranbaxy deal approval.....           Deal-hungry Pfizer reportedly made a (failed) run at Teva. Who's next?.....           Ready to spar with Pfizer's meningitis B jab, Novartis gets FDA green light for Bexsero.....           J&J again faces off-label marketing claims in Risperdal case of boy who grew breasts.....           Actavis plunks down $460M for U.K. generics specialist Auden Mckenzie.....           Gilead discounts hep C meds in Germany, offers new-and-improved generics deal in India.....           Novo Nordisk puts 500 Saxenda reps on U.S. streets, aiming for $1B in weight-loss sales.....           Generic of AstraZeneca's Nexium finally hits the market with Teva getting FDA nod.....           Supreme Court pitches patent fight over Shire's Lialda after Teva ruling.....           ImmuPharma, Simbec-Orion collaborate to execute Phase III Lupuzor trial for Lupus.....           Alexza begins Phase IIa trial of AZ-002 to treat epilepsy patients.....           EMA recommends sale suspension of medicines based on GVK Bio?s ?flawed? clinical data.....           Scientist finds way to improve antibiotics to treat staph infections.....           FDA committee recommends approval of Astellas' Cresemba.....           NovaMedica gets Russian rights for three gastrointestinal products from Omega Pharma.....           FDA clears Advaxis' IND application to conduct Phase I trial of ADXS-HER2.....           Aprea's ovarian cancer drug candidate APR-246 gets European orphan drug status.....           Pfizer's Prevenar 13 gets CHMP positive opinion for prevention of vaccine-type pneumococcal pneumonia in adults.....           Syncona, UCLB form cancer immunotherapy firm Autolus.....           WCCT global enters into clinical research partnerhip with DynPort Vaccine Company.....           TiGenix gets European patent relating to adipose-derived stem cell composition.....           CytRx reports overall survival results from phase IIb trial of aldoxorubicin.....           Taiwan moves to cut reimbursement costs by switching 13 drugs to OTC.....           GSK refutes reports the ax is about to fall on jobs in China.....           Challenger says 2015 a year to send out your resume, pharma folks.....           Trans-Pacific Partnership push waits on cue from Obama's India visit.....           Novo hopes for European Saxenda launch this year after CHMP nod.....           Celgene's Abraxane wins another OK in Europe.....           Kineta closes patient enrollment in Phase Ib trial of ShK-186 to treat psoriasis.....           EMA accepts AstraZeneca's MAA for gout treatment lesinurad.....           Genzyme's Cerdelga gets European marketing authorization for Gaucher Disease.....           U.S. Supreme Court ruling on Copaxone triggers questions in generics-minded India.....           Novartis eyes psoriasis dominance with new approvals for Cosentyx.....           Curis, Aurigene partner to develop precision oncology targets.....           Minerva Neurosciences reports positive phase I data with MIN-202.....           UCB announces US and EU regulatory filings for brivaracetam.....           Kinex doses first patient with KX2-391 ointment for actinic keratosis in Phase I trial.....           Trovagene expands clinical collaboration with Genomac.....           OncoSynergy's cancer drug OS2966 gets FDA orphan drug status.....           India issues draft bioequivalence request format for drugs aimed for export.....           Novartis eyes psoriasis dominance with new approvals for Cosentyx.....           Rooting for a French CEO at Sanofi? Take another name off your list of prospects.....           Valeant CEO admits 'major miscalculation' in failed quest to nab Allergan.....           Gilead's John Martin scores 'best CEO' trophy for huge stock gains.....           Europe accepts AstraZeneca's gout drug app, keeping blockbuster hopes alive.....           Ex-Sanofi chief Viehbacher makes a $5M-plus severance deal.....           AM-Pharma initiates Phase II trial of recAP in AKI patients.....           FDA approves Novartis' Cosentyx to treat plaque psoriasis.....           Boehringer launches Spiriva Respimat in US.....           FDA grants fast track status for Celator's leukemia drug CPX-351.....           Pharmalink's IND application for IgA Nephropathy now open with FDA.....           Ocular begins patient enrolment in dexamethasone Phase II trial for dry eye disease.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

  • Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
  • Share learning, drive collaboration, partnership and innovation
  • Deliver insights into industry and academic roles for aspiring scientists
Latest News
APS Bioequivalence of Orally Inhaled Drug Products: Establishing the Scientific Basis for Regulatory Acceptance of In Vitro Strategies
NHLI, Imperial College, London Monday 30th March 2015 . APS and the Aerosol Society Joint Symposium.. The European Medicines Agency published its “Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP)” in 2009. The regulatory clarity the guidelines have provided has revealed scientific hurdles particularly relating to how inhalation and regulatory scientists can define bioequivalence for inhaled therapies. A particular challenge has emerged in establishing the nature of in vitro-in vivo correlations and the poor predictability of pulmonary bioavailability data from in vitro pharmaceutical performance testing. This meeting will bring together inhalation scientists from academia, regulatory agencies, innovator, and generic pharmaceutical developers. The symposium will assess the current scientific knowledge base and identify the challenges that must be addressed in identifying appropriate and meaningful in vitro metrics that are predictive of bioavailability. There will be thought-provoking short-talks by key opinion leaders from a regulatory background and from innovator and generic pharmaceutical industrial scientists. The talks will stimulate facilitated breakout sessions to identify opportunities to address the scientific challenges. The symposium aims to establish a consensus ‘white paper’ on the key components of a joint academic-industrial-regulatory research programme to develop tools that support the in vitro approach for OIP licensing.. For more information, to view the programme and to register for the conference, please visit the APS website here:
Bill Dawson - Chair of APS speaks to BBC Radio Leicester about cost of developing new medicines
Cancer therapies have increased in cost to the NHS, notably with the licensing of the latest biotechnology products. The Government has sought to help by creating the Cancer Drug Fund but even with increases in this budget it has still been necessary to take medicines off the funded list.. With this background, Radio Leicester decided to run a 30 minute programme on January 15 as a debate on the costs of developing new medicines and to ask the question were drug companies charging too much. The panel they asked to contribute included Bill Dawson, Chair of the Academy of Pharmaceutical Sciences, Stephen Dorrell, MP for Charnwood, Elisabeth Sukkar, Senior Editor from the Pharmaceutical Journal and Zuffur Haq, a local Leicester health care advocate. The panel was well presented and moderated by Jonathan Lampon. The debate was informative and is available, with kind regards to the RPS at:
DMU Free Evening Seminar: QbD for Biopharmaceuticals: Progress and Opportunities
16:30 – 19:30 Tuesday 13th January 2015 MedImmune, Cambridge GUEST SPEAKERS Tim Schofield, MedImmune Keith Chidwick, MHRA Bruno Boulanger, Arlenda PROGRAMME 16:30Arrive and tea and coffee17:00Opening Remarks, Paul Varley, VP, Biopharmaceutical Development, MedImmune17:05Introduction by De Montfort University17:15Timothy Schofield, Senior Fellow, Regulatory Sciences & Strategy, Analytical Biotechnology, MedImmune17:50Keith Chidwick, Senior Pharmaceutical Assessor, MHRA18:20 Bruno Boulanger, Professor at University of Liège, Belgium, CSO at Arlenda SA.18:45Closing remarks18:50Networking drinks and canapés De Montfort University’s Quality by Design group would like to invite you to attend the launch event for our new distance learning module in Quality by Design for Biopharmaceuticals. The event will provide a chance to learn more about the DMU QbD distance learning course, to learn from the experiences of our guest speaker and to network with other biopharmaceutical scientists and professionals.. Places are limited so reserve your place today: Email: For further information about the DMU’s new Biopharmaceuticals module see: For further information about QbD at DMU go to: Enrolling now for distance learning courses in Quality by Design. Visit to find out more! .
Cross-Industry Organizations: An update on activities of the Drugs in the Lung Network in inhalation
The Drugs in the Lung Network was devised with the aim of providing cross-company collaboration and developing industry-academia pre competitive consortia. It acts as a sub group of the Inhalation Focus Group, and has published an article in Inhalation reviewing recent events and looking forward to 2015/2016. Click here for more information and a copy of the article. .
Follow us
Upcoming Events
APS Bioequivalence of Orally Inhaled Drug Products: Joint Meeting with The Aerosol Society
30 March 2015
APS Particle Engineering - Joint Meeting with SSPC
13 - 14 April 2015
APS Industrial Insights 2015
16 - 17 April 2015
APS Board Meeting
28 - 29 April 2015
APS Parkinson's Disease: From Patient to Product
19 May 2015
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.